Sign In  |  Register  |  About Livermore  |  Contact Us

Livermore, CA
September 01, 2020 1:25pm
7-Day Forecast | Traffic

  • Search Hotels in Livermore

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ark Genomic Revolution ETF (NY: ARKG )

24.78 -0.08 (-0.32%)
Streaming Delayed Price Updated: 9:34 AM EDT, Oct 7, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Ark Genomic Revolution ETF

< Previous 1 2 3 4 5 6 7 8 9 Next >
Benzinga Asks: Which ARK Fund Would You Rather Buy And Hold For 5 Years?
One of the best-known and well-covered ETF companies over the past five years has been ARK Invest, led by Cathie Wood. With t... 
Via Benzinga
A Leaky ARKK
In a year when everything skyrocketed to nauseating highs, Cathie’s momentum-obsessed investing style was a dud. 
Via Talk Markets
UiPath Stock Is Worth Believing in Here as Wood Holds Fast
Cathie Woods ARK Investment ETFs have loaded up on shares of UiPath despite the decline. PATH stock has plenty of upside from here. 
Via InvestorPlace
Biotech Playbook 2021 Part 2: Rotation Rally Brings Relief after FED Pivot
The new aggressive Fed taper combined with a rise in interest rates for 2022 adds a new element of risk to portfolio management. Monetary policy is a headwind for 2022. 
Via Talk Markets
Neck Cream Reversal
Cathie Wood's ARKG is down about 50% over the past 9 months. 
Via Talk Markets
Cathie Wood Added To Stake In This Medical Technology Company As Its Shares Surged 6% On Friday
Cathie Wood’s Ark Investment Management on Friday bought 26,126 shares — estimated to be worth $163,026 — in Quantum-Si Inc (NASDAQ: QSI). Shares of the medical... 
Via Benzinga
Biotech Playbook 2021: No Help From Small Caps In Q4
Mid-cap stock picks have done better today but are way off their 2021 highs. Cryoport and Veracyte are still up and look better technically. Quidel was up 5.48% today on Omicron concerns globally but... 
Via Talk Markets
Bionano Genomics Proves Not Everything Genetic is Gold
Bionano sells a $150,000 machine called Saphyr that does genetic mapping. It's a solid device, but its future remains in the future, as do BNGO stock fortunes. 
Via InvestorPlace
Cathie Wood Testing 'ARK On Steroids' As ARK Funds Struggle
Wood said ARK is testing a strategy to short stocks in the big benchmark indexes, 
Via Investor's Business Daily
Topics Electric Vehicles
Exposures Electric Vehicles
Don't Look Now, But Cathie Wood's Ark Is Taking On Water
Among the biggest losers over the last 48 hour tech stock volatility has been...well, everything in Cathie Wood's 
Via Talk Markets
Biotech Stocks are Due for a Rally
There are many rebalancing trades left in your stock portfolio but biotech is in the doldrums. 
Via Talk Markets
Yes, Cathie Wood's $700,000 Bitcoin Price Prediction Is Legit
A Bitcoin price prediction of $700,000 - more than 10 times the recent price - would strike most people as delusional. But this eye-popping target doesn't come from a Bitcoin fan. It comes from Wall... 
Via Talk Markets
Tesla (TSLA) Not Enough To Lift ARK Innovation (ARKK)
An updated look at Cathie Wood’s ARK ETFs relative strength versus the S&P 500 SPY ETF. 
Via Talk Markets
Topics Stocks
Exposures US Equities
ETF Battles: Finding the Top Genomics Biotech ETF – A Triple Header of ARKG vs IDNA vs GNOM
The search for therapies tackling chronic illnesses like cancer, diabetes, and heart disease has put stocks in the biotechnology and genomics industry sector on center stage. 
Via Talk Markets
Ginkgo Bioworks Stock Drops 20% After Short Sellers Call Company A 'Colossal Scam'
Shares of synthetic biology company Ginkgo Bioworks Holdings Inc (NYSE: 
Via Benzinga
Mike Khouw Sees Unusual Options Activity In ARK Genomic Revolution ETF
On CNBC's "Options Action," Mike Khouw said ARK Genomic Revolution ETF (BATS: ARKG) was active on Tuesday as it traded six times its average daily put volume.... 
Via Benzinga
Biotech Playbook Revisited As Technicals Weaken
Recent breakthroughs with mRNA vaccines over the past two years have shown the enormous potential for transformative therapies. DNA sequencing took off five years ago and new applications are still... 
Via Talk Markets
Look For The Q4 Biotech Bounce In Mid-Small Caps
Large-cap biopharma stocks are off their highs because of prospects that drug prices may be directly negotiated through Medicare but several Democrats are not in agreement as to how this could be best... 
Via Talk Markets
Small Cap Biotechs Sagging But More Deals Are Likely to Perk Up the Market
Despite record highs in the Nasdaq recently at the 15,000 level the biotech market seems sluggish. Speculation has ebbed. As if we need a green screen every day. 
Via Talk Markets
3 Healthcare Stocks Cathie Wood Loves Right Now
Here's why the founder and CEO of ARK Invest set her sights on these three healthcare stocks. 
Via The Motley Fool
Healthcare Stocks Hit New Highs but Small Caps Lag
Many smaller cap biotech stocks trade on news and milestones and have no earnings so require more expertise in the field. 
Via Talk Markets
Cathie Wood's Ark Adds Another $29M To Palantir Stake After Q2 Earnings Beat, Buys DraftKings On Dip
Cathie Wood-led Ark Invest on Friday snapped up 1.156 million shares — estimated to be worth about $28.78 million — in... 
Via Benzinga
Topics Earnings
Exposures Financial
Palantir, Alibaba, Square, Twitter, DraftKings — Stocks Cathie Wood's Ark Bought Or Sold On Thursday
Cathie Wood-led Ark Invest on Thursday increased the exposure in Palantir Technologies Inc (NYSE... 
Via Benzinga
Teladoc's Earnings Had 1 Important Metric for Both Bulls and Bears
Which story do you believe? 
Via The Motley Fool
As Zymergen Crashes 76%, Cathie Wood Piles Up $2.5M Worth Of Shares
A bullish Ark Invest on Wednesday more than doubled its stake in Zymergen Inc (NASDAQ: ZY) after it plummeted due to the company’s “immaterial” revenue... 
Via Benzinga
Q2 Growth 'Nothing Short Of Virtuous': Economist
The coronavirus pandemic that began in 2020 and is persisting today has led many investors to hold poor market expectations. But maybe they shouldn’t be so pessimistic. What... 
Via Benzinga
Exposures COVID-19
Cathie Wood Doubles Down On Teladoc, Spotify, Shopify As Stocks See Earnings-Related Dips
Cathie Wood-led Ark Investment Management on Wednesday piled up 713,842 shares, estimated to be worth about $108.37 million, in 
Via Benzinga
Cathie Wood's Ark ETFs Underperformed The Broader Market In Q2, With Workhorse, Virgin Galactic, Coinbase, Teladoc Taking Big Toll
ARK Invest, the New York-based investment management firm led by the popular money manager Cathie Wood, saw its five actively managed exchange-traded funds and two self-indexed... 
Via Benzinga
A Comprehensive Guide To Genomic ETFs
Given the growing applications of gene-editing, it is a rising market which offers endless opportunities. Growing demand for personalized medicine, solid investments and higher R&D activities will soon... 
Via Talk Markets
Where Will ARK Genomic Revolution ETF Be in 5 Years?
Cathie Wood's genomics ETF is making big bets on the "Genomic Age." 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Livermore.com & California Media Partners, LLC. All rights reserved.